Meet Your Case Manager, Shontae

Case Manager Shontae

My Experience

I have more than 12 years of experience providing case management to the rare disease community.

My Inspiration

As an Alnylam Case Manager, I am able to help patients overcome barriers and explore ways to access care. My decision to remain positive in challenging times and witness the benefit of that attitude inspires me every day.

Why I Love What I Do

I love helping people who feel stuck by guiding them through their individual healthcare challenges.

My Superpower

Resilience. It is when we feel our weakest that we must be our strongest.

Favorite Things

I participate in initiatives for women to address the issues that threaten their ability to practice self-care. In these settings, we explore ways to practice self-care and identify the behaviors (like guilt) that make it difficult.

As a social worker for the state, I served a population during their most vulnerable and challenging times. This experience led me down the path to continue helping people in need.


Shontae, Case Manager

Alnylam Assist® get started icon

See How to Get Started

Once you and your doctor decide to begin treatment with OXLUMO, we'll work with your healthcare team to start the process.

How to Get Started
Alnylam Assist® Case Manager Shontae

Call Shontae


Monday - Friday, 8am - 6pm ET

Alylam Separator Triangles


The most common side effect of OXLUMOTM (lumasiran) is injection site reaction (redness, pain, itching, and swelling at the site of injection). These are not all the possible side effects of OXLUMO. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.

OXLUMO has not been studied in pregnant or breastfeeding women. Talk to your doctor about the risk of taking OXLUMO if you are pregnant, plan to become pregnant, are breastfeeding, or plan to breastfeed.


OXLUMO is a prescription medicine for the treatment of primary hyperoxaluria type 1 (PH1) to lower oxalate in urine in children and adults.

For additional information about OXLUMO, please see the full Prescribing Information.